Signal Genetics (NASDAQ: SGNL) is a commercial-stage molecular design company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company’s lead product is its MyPRS® test, which is a microarray-based gene expression profile assay designed to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma. For more information, visit the company’s website at www.signalgenetics.com.